NBIX insider buying and SEC filings, explained
Neurocrine Biosciences Inc. · CIK 914475
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq
- Industry (SIC)
- Biological Products, (No Diagnostic Substances)
- State of incorporation
- DE
- Fiscal year end
- Dec 31
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$0
Planned sales (10b5-1)
$80.2M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Oct 30–Nov 3, 2026 | Planned (10b5-1) | George J. Morrow (Director) sold 15,000 shares between Oct 30 and Nov 3 at about $155.73 ($2.3M), marked as a 10b5-1 plan trade. Holdings down 59% to 10,386 shares. | SEC filing Filed Nov 3, 2026, 6:52 PM ET |
| Sep 14, 2026 | Planned (10b5-1) | David W. Boyer (Chief Corp. Affairs Officer) sold 826 shares at about $157.45 ($130K), marked as a 10b5-1 plan trade. Holdings down 9% to 8,722 shares. | SEC filing Filed Sep 15, 2026 |
| Sep 14, 2026 | Planned (10b5-1) | Matt Abernethy (CFO) sold 2,311 shares at about $157.20 ($363K), marked as a 10b5-1 plan trade. Holdings down 5% to 42,808 shares. | SEC filing Filed Sep 15, 2026 |
| Sep 9, 2026 | Planned (10b5-1) | Eric Benevich (Chief Commercial Officer) sold 2,154 shares at $154.61 ($333K), marked as a 10b5-1 plan trade. Holdings down 3% to 64,408 shares. | SEC filing Filed Sep 10, 2026 |
| Jul 28, 2026 | Planned (10b5-1) | Leslie V Norwalk (Director) sold 1,250 shares at about $182.01 ($228K), marked as a 10b5-1 plan trade. Holdings down 44% to 1,588 shares. | SEC filing Filed Jul 30, 2026 |
| Jul 10, 2026 | Planned (10b5-1) | Ingrid Delaet (Chief Regulatory Officer) sold 4,367 shares at $181.02 ($791K), marked as a 10b5-1 plan trade. Holdings down 21% to 16,225 shares. | SEC filing Filed Jul 13, 2026 |
| Jul 9, 2026 | Planned (10b5-1) | Darin Lippoldt (Chief Legal Officer) sold 10,000 shares at about $179.60 ($1.8M), marked as a 10b5-1 plan trade. Holdings down 15% to 54,729 shares. | SEC filing Filed Jul 13, 2026 |
| Jul 7–9, 2026 | Planned (10b5-1) | Ingrid Delaet (Chief Regulatory Officer) sold 14,571 shares between Jul 7 and Jul 9 at about $178.65 ($2.6M), marked as a 10b5-1 plan trade. Holdings down 47% to 16,225 shares. | SEC filing Filed Jul 9, 2026 |
| Jun 26–29, 2026 | Planned (10b5-1) | Darin Lippoldt (Chief Legal Officer) sold 10,000 shares between Jun 26 and Jun 29 at about $170.15 ($1.7M), marked as a 10b5-1 plan trade. Holdings down 15% to 54,729 shares. | SEC filing Filed Jun 30, 2026 |
| Jun 5, 2026 | Planned (10b5-1) | Stephen A. Sherwin (Director) sold 25,000 shares at about $165.32 ($4.1M), marked as a 10b5-1 plan trade. Holdings down 61% to 15,860 shares. | SEC filing Filed Jun 9, 2026 |
| Jun 4, 2026 | Planned (10b5-1) | Leslie V Norwalk (Director) sold 1,250 shares at about $168.06 ($210K), marked as a 10b5-1 plan trade. Holdings down 31% to 2,838 shares. | SEC filing Filed Jun 8, 2026 |
| Jun 2, 2026 | Planned (10b5-1) | Julie Cooke (Chief Human Resources Officer) sold 36,937 shares at about $156.22 ($5.8M), marked as a 10b5-1 plan trade. Holdings down 62% to 22,374 shares. | SEC filing Filed Jun 4, 2026 |
| Jun 1, 2026 | Planned (10b5-1) | Jude Onyia (Chief Scientific Officer) sold 11,000 shares at about $160.25 ($1.8M), marked as a 10b5-1 plan trade. Holdings down 30% to 25,846 shares. | SEC filing Filed Jun 2, 2026 |
| May 29, 2026 | Planned (10b5-1) | Ingrid Delaet (Chief Regulatory Officer) sold 2,261 shares at $156.71 ($354K), marked as a 10b5-1 plan trade. Holdings down 12% to 16,225 shares. | SEC filing Filed Jun 2, 2026 |
| May 27, 2026 | Planned (10b5-1) | Jude Onyia (Chief Scientific Officer) sold 11,000 shares at about $155.53 ($1.7M), marked as a 10b5-1 plan trade. Holdings down 30% to 25,846 shares. | SEC filing Filed May 29, 2026 |
| May 26, 2026 | Planned (10b5-1) | David W. Boyer (Chief Corp. Affairs Officer) sold 3,888 shares at about $156.64 ($609K), marked as a 10b5-1 plan trade. Holdings down 33% to 7,799 shares. | SEC filing Filed May 28, 2026 |
| May 19, 2026 | Planned (10b5-1) | Kevin Charles Gorman (Director) sold 245,088 shares at about $154.33 ($37.8M), marked as a 10b5-1 plan trade. Holdings down 32% to 511,293 shares. | SEC filing Filed May 21, 2026 |
| May 15, 2026 | Planned (10b5-1) | Richard F. Pops (Director) sold 15,000 shares at about $157.65 ($2.4M), marked as a 10b5-1 plan trade. Holdings down 30% to 34,480 shares. | SEC filing Filed May 18, 2026 |
| May 12, 2026 | Planned (10b5-1) | Leslie V Norwalk (Director) sold 3,810 shares at about $155.01 ($591K), marked as a 10b5-1 plan trade. Holdings down 61% to 2,429 shares. | SEC filing Filed May 14, 2026 |
| Jan 16, 2026 | Planned (10b5-1) | Kyle Gano (CEO and Director) sold 36,400 shares at about $132.70 ($4.8M), marked as a 10b5-1 plan trade. Holdings down 21% to 140,407 shares. | SEC filing Filed Jan 20, 2026 |
| Dec 15–16, 2025 | Planned (10b5-1) | Leslie V Norwalk (Director) sold 6,190 shares between Dec 15, 2025 and Dec 16, 2025 at about $152.78 ($946K), marked as a 10b5-1 plan trade. Holdings down 50% to 6,239 shares. | SEC filing Filed Dec 17, 2025 |
| Dec 8, 2025 | Planned (10b5-1) | Darin Lippoldt (Chief Legal Officer) sold 4,376 shares at about $159.65 ($699K), marked as a 10b5-1 plan trade. Holdings down 9% to 43,405 shares. | SEC filing Filed Dec 10, 2025 |
| Dec 3, 2025 | Planned (10b5-1) | Gary A. Lyons (Director) sold 15,000 shares at about $152.61 ($2.3M), marked as a 10b5-1 plan trade. Holdings down 11% to 120,482 shares. | SEC filing Filed Dec 4, 2025 |
| Nov 28, 2025 | Planned (10b5-1) | Eric Benevich (Chief Commercial Officer) sold 5,970 shares at about $151.74 ($906K), marked as a 10b5-1 plan trade. Holdings down 12% to 44,893 shares. | SEC filing Filed Dec 2, 2025 |
| Nov 25, 2025 | Planned (10b5-1) | George J. Morrow (Director) sold 15,000 shares at about $143.37 ($2.2M), marked as a 10b5-1 plan trade. Holdings down 68% to 7,068 shares. | SEC filing Filed Nov 26, 2025 |
| Nov 5, 2025 | Planned (10b5-1) | William H. Rastetter (Director) sold 18,000 shares at about $151.82 ($2.7M), marked as a 10b5-1 plan trade. Holdings down 31% to 40,360 shares. | SEC filing Filed Nov 6, 2025 |
| Nov 4, 2025 | Planned (10b5-1) | Kyle Gano (CEO and Director) sold 300 shares at $141.97 ($43K), marked as a 10b5-1 plan trade. Holdings down <1% to 140,407 shares. | SEC filing Filed Nov 4, 2025 |
79 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
| Filed | Items | Tag | Source |
|---|---|---|---|
| Nov 2, 2026, 4:11 PM ET 8-K | Earnings released (Item 2.02) | SEC filing |
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow NBIX in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.